The 2026 trading year has kicked into gear, and while some stocks are already pushing higher into the green, others are ...

The Buck Moon gets its name from when the new antlers of buck deer push out from their foreheads in coatings of velvety fur ...

When security vulnerabilities appear in popular frameworks, they can affect thousands of websites overnight. That’s exactly what’s happening with a newly discovered vulnerability in Next.js – one of ...

Find out the most popular baby names for boys and girls in 2025, according to BabyCenter. The Social Security Administration ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Cathie Wood’s ARK Investment Management sharply increased its exposure to AI-driven biotechnology and cryptocurrency during ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...